In Stock
Lenvatinib Capsules
Lenvatinib Capsules 4mg | Anti-Cancer
- Product Form: Raw Powder / API
- Not for direct consumer use
- For qualified buyers, formulation, compounding, R&D, and regulated business use only
- COA/MSDS available upon request
- Final sale depends on buyer country import regulations
Disclaimer: Products listed on this website are intended for qualified business buyers, research, formulation, compounding, or regulated pharmaceutical use only. Products are not intended for direct consumer use. Import permission, registration, customs clearance, and local regulatory compliance are the responsibility of the buyer in their respective country.
Description
Generic medicine information • For patient education
Product Introduction
Lenvatinib 4 mg is a prescription anti-cancer medicine in the tyrosine kinase inhibitor (TKI) class. It is used for selected cancers, including differentiated thyroid cancer, liver cancer, kidney cancer, and certain endometrial cancers, depending on the diagnosis and treatment plan. An oncology specialist must decide whether it is appropriate.
The 4 mg strength is the amount in each capsule; it does not mean that every patient should take only 4 mg. The dose and schedule depend on the cancer type, body weight where relevant, other medicines, response, and side effects.
1. Uses
Selected cases of differentiated thyroid cancer.
Selected cases of liver cancer (hepatocellular carcinoma), when indicated by the treating specialist.
Kidney cancer, generally as part of a combination regimen in selected patients.
Certain advanced or recurrent endometrial cancers, often in combination with another anti-cancer medicine, according to the approved indication.
The exact use and any combination treatment must be confirmed by the treating oncologist.
2. Benefits
Blocks specific tyrosine kinase proteins involved in cancer-cell growth and tumour blood-vessel formation.
By reducing signals that support tumour growth and blood supply, it may help control disease or slow progression in appropriately selected patients.
Benefits vary by cancer type and individual; treatment is not a guaranteed cure.
3. Side Effects
Common or reported side effects include high blood pressure, diarrhoea, nausea, vomiting, mouth inflammation (stomatitis), headache, reduced appetite, weight loss, fatigue, abdominal pain, joint or muscle pain, protein in the urine, bleeding, and hand-foot skin reactions.
Serious risks can include severe high blood pressure, major bleeding, liver injury, heart problems, abnormal heart rhythm, kidney problems, thyroid changes, blood clots, delayed wound healing, and rarely gastrointestinal perforation or a serious brain condition called PRES.
Seek urgent medical help for severe headache with confusion or vision changes, chest pain, sudden breathlessness, fainting or seizures, heavy bleeding, black stools or blood in urine, severe abdominal pain, yellow skin/eyes, or severe/persistent diarrhoea or vomiting.
4. Safety Advice
Tell your oncology team if you have high blood pressure, heart disease, liver or kidney problems, thyroid disease, bleeding problems, or a planned surgery.
Regular monitoring may include blood pressure, liver and kidney function, thyroid function, urine protein, blood tests, calcium levels, and heart checks as advised.
Pregnancy: lenvatinib may harm an unborn baby. Tell your doctor if pregnant, planning pregnancy, or if pregnancy is possible. Use reliable contraception during treatment and for the period advised by your specialist after the last dose.
Breastfeeding: do not breastfeed during treatment; ask your specialist when it may be safe to resume.
Surgery or dental procedures: tell your surgeon and dentist that you take lenvatinib because it may delay wound healing and can increase certain complications. Your oncology team may advise a treatment pause.
Driving: avoid driving or operating machinery if you feel dizzy, weak, or have symptoms that affect concentration or vision.
Alcohol: it is not known whether alcohol is safe with lenvatinib; ask your oncology team.
Kidney or liver disease: use requires medical review and may need adjustment or closer monitoring.
Storage: store below 30°C, in the original packaging and out of reach of children, unless the product leaflet says otherwise.
5. How It Works
Lenvatinib inhibits several receptor tyrosine kinases involved in tumour-cell growth and the development of blood vessels that supply a tumour. This can slow the growth and spread of certain cancers.
6. How to Use
Take exactly as prescribed by your oncologist. The prescribed dose may be different from the 4 mg strength printed on the capsule.
Lenvenib 4 mg capsule may be taken with or without food. Try to take it at the same time each day.
Swallow the capsule as directed with water. Do not change the dose or stop treatment without speaking to your oncology team.
If you miss a dose or vomit after taking it, follow the package leaflet or contact your oncology team for instructions; do not double a dose unless specifically told to do so.
Do not share this medicine with anyone else.
7. Quick Tips
Monitor blood pressure regularly and report severe headache, confusion, vision changes, or very high readings promptly.
Attend all scheduled tests, especially blood pressure, liver/kidney function, thyroid function, and urine protein checks.
Report bleeding, persistent diarrhoea or vomiting, severe abdominal pain, or signs of dehydration promptly.
Tell your care team about all prescription medicines, over-the-counter medicines, vitamins, and herbal supplements.
Use reliable contraception as advised and do not breastfeed during treatment.
Report slow-healing wounds and tell your healthcare team before any planned surgery or dental procedure.
8. Drug Interactions
Lenvatinib can interact with medicines that affect heart rhythm, including some medicines that prolong the QT interval. Examples flagged on the Tata 1mg page include amiodarone, thioridazine, pimozide, haloperidol, and sotalol.
Other medicines and supplements may also affect treatment safety. This is not a complete interaction list.
Do not start, stop, or change any prescription medicine, over-the-counter product, or supplement without checking with your oncologist or pharmacist.
Medical Disclaimer
This document is for general patient education only and is not a substitute for advice from a qualified doctor, oncology specialist, or pharmacist. Lenvatinib is a prescription anti-cancer medicine and must be used only under specialist supervision. The correct indication, dose, monitoring, precautions, and management of side effects depend on the individual patient and current approved product information. In an emergency, seek urgent medical care.
| Product Name | Lenvatinib Capsules |
| Category | All Medicines, Anti Cancer |
| Form | Raw Powder |
| Grade | As per available specification |
| Documents | COA, MSDS, Invoice, Packing List |
| Packing | As per order quantity |
| MOQ | On request |
| Shipment | Air cargo / courier / buyer-approved route |
| Use | B2B, formulation, compounding, research & qualified buyer supply |
| Disclaimer | Subject to buyer country regulations |
Additional information
| Strength | 4mg |
|---|
Customer Reviews
Only logged in customers who have purchased this product may leave a review.
